drugset / Trial / NCT01434602
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma. The goal of Phase 2 of this study to learn if the combination of everolimus and sorafenib can help to control malignant glioma. The safety of this combination will also be studied in both phases.
Timeline
- Start
- 2012-10-02
- Primary completion
- 2020-10-19
- Completion
- 2021-07-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Sorafenib | Small molecule | 600 mg | Oral |
| Subject | Sorafenib | Small molecule | 800 mg | Oral |